Tumor Mutational Load: A Novel Predictor for Clinical Benefit of Pembrolizumab.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 38976040.
- Also identified by DOI 10.1158/1078-0432.CCR-24-1261.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A recent study evaluated the efficacy of pembrolizumab across various cancers, classified according to tumor mutational load (TML) defined by whole-genome sequencing. Tumors exhibiting intermediate to high TML showed improved clinical benefit from pembrolizumab. This proof-of-concept study highlights clinical value of TML in patient selection, advancing precision immunotherapy and treatment strategies. See related article by Geurts et al., p. 3735.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Mutation
- Neoplasms
- Antineoplastic Agents, Immunological